Last updated: May 26, 2026
Suppliers for Donepezil Hydrochloride and Memantine Hydrochloride: Who Manufactures API and How Supply Chains Are Typically Structured
Donepezil hydrochloride and memantine hydrochloride have multiple global suppliers across API manufacturing, intermediate synthesis, and finished-dose sourcing. In practice, supply is split between (1) API producers that sell directly to generic and branded formulators, (2) contract manufacturers that package finished dosage forms, and (3) distributors with portfolio contracts. For procurement, the highest-risk gaps usually sit in late-stage API intermediates, specific polymorph/hydrate control, and finished-dose regulatory dossiers rather than in headline API availability.
Which companies supply donepezil hydrochloride API and intermediate chemicals?
Donepezil hydrochloride (CAS 120247-27-8) is commonly sourced as GMP API by generic manufacturers and marketers in the US, EU, and Asia. The supplier set tends to include Chinese and Indian API firms plus a smaller tier of Western-qualified distributors and toll packagers that do not own upstream synthesis.
What API form do buyers typically require for donepezil hydrochloride?
Procurement specifications typically include:
- Identity and assay (HPLC/GC methods)
- Impurity profile aligned to pharmacopeia and drug master file (DMF) filings
- Water content or hydrate form control, plus particle size where relevant to tableting
- Residual solvents and heavy metals limits
- Polymorph/hydrate specifications where vendors use controlled crystallization steps
What finished-dose supply chain exists for donepezil hydrochloride tablets?
Finished-dose supply commonly flows as:
- API supplier to
- formulation manufacturer (site-specific) to
- packaging and label (in some cases at another site) to
- importer/distributor for regional release.
Donepezil is frequently made as immediate-release tablets (including 5 mg and 10 mg) and as higher-dose regimens depending on jurisdiction.
Which companies supply memantine hydrochloride API and finished-dose product?
Memantine hydrochloride (CAS 41100-52-1) is also widely available as GMP API. As with donepezil, the market is characterized by multi-sourcing, with a procurement emphasis on consistent impurity control and solid-state behavior for direct-compression and film-coating performance.
What API specifications do memantine buyers focus on?
Key procurement focus areas include:
- Impurity and degradant set matching regional pharmacopeia expectations and filings
- Residual solvent compliance
- Salt form control (hydrochloride) and stability
- Particle size distribution for blend uniformity in low-dose cores
What finished-dose formats are commonly sourced for memantine?
Memantine is commonly supplied in tablets (including 5 mg and 10 mg) and may also appear in combination products with donepezil depending on region.
How does supply differ between donepezil hydrochloride and memantine hydrochloride?
Donepezil tends to be sensitive to tablet performance parameters tied to particle size and crystallization batches. Memantine procurement often emphasizes consistent hydrochloride salt quality and impurity control because manufacturing routes can vary by intermediate sourcing.
What are the recurring supply constraints?
Across both actives, recurring constraints usually include:
- upstream intermediate availability during peak capacity periods
- change-control delays when switching polymorph/hydrate grade or crystallization parameters
- documentation timelines for DMF cross-referencing and quality agreements
What contracts and qualification standards govern donepezil and memantine supplier onboarding?
Supplier onboarding generally requires:
- GMP compliance at the API site
- quality agreements covering specifications, change notifications, OOS/OOT handling, and stability
- audit readiness for documentation covering batch records, analytical methods, and method validation
- compatibility with DMF/ASMF reference needs for US FDA and EMA regulatory filings (as applicable)
How do buyers reduce risk in multi-sourcing?
Procurement programs typically:
- qualify at least two API sources per strength/formulation
- require bridging stability and impurity comparability studies when switching suppliers
- standardize acceptance criteria for key impurities and residual solvents
- align packaging and logistics validation for shelf-life maintenance
What distributors provide donepezil and memantine API in practice?
In addition to direct API manufacturers, distributors with global lanes supply API to formulators. These intermediaries usually:
- hold inventory for faster lead times
- manage documentation packets for regulatory use cases
- bundle API with excipients or support toll blending programs
Supplier qualification still typically anchors to the underlying API manufacturer’s GMP compliance and documentation.
Which regions have the most active API supply for donepezil and memantine?
API supply is concentrated in Asia, with China and India the most active for GMP API for both actives. European and US vendors more frequently operate as distributors, toll manufacturers, or dossier/CMC service providers, with fewer owning full upstream synthetic routes at scale.
What does “regionally qualified” mean for buyers?
“Qualified” generally means:
- GMP site approval via audits
- DMF/ASMF applicability for regulatory submissions
- stable performance in comparability studies for the buyer’s formulation
How do combination products influence donepezil and memantine sourcing?
For combination products that include both actives (donepezil + memantine), supply coordination becomes a gating factor. Buyers often need:
- synchronized lead times for both APIs
- compatible particle size and excipient blend behavior
- aligned impurity acceptance ranges that match the finished-dose specification
This can reduce the feasible supplier subset for one active if the other active’s availability is constrained.
Key Takeaways
- Donepezil hydrochloride and memantine hydrochloride are multi-sourced APIs with the largest supplier concentrations in Asia.
- Supplier risk concentrates on batch-to-batch quality consistency, impurity profiles, and solid-state control rather than outright API availability.
- Qualification typically requires GMP compliance, quality agreements, audit readiness, and regulatory documentation alignment (DMF/ASMF references).
- For combination products, dual-API supply synchronization is the main operational constraint.
FAQs
1) How many API suppliers typically qualify for donepezil hydrochloride tablets?
Multi-source strategies commonly qualify two or more API suppliers per tablet strength to reduce disruptions from intermediate shortages and change-control delays.
2) What impurity issues most often drive reformulation for memantine hydrochloride?
Impurity set drift tied to upstream intermediate routes and degradant control during crystallization and drying can force bridging work and CMC change submissions.
3) Are donepezil hydrochloride and memantine hydrochloride supplied by the same manufacturers?
Some manufacturers supply both actives, but qualification often occurs independently because solid-state behavior, impurity profile, and dossier expectations differ by API and site.
4) What documentation is required to switch donepezil or memantine API suppliers?
Quality agreements plus bridging stability and impurity comparability are typical, alongside updated CMC references and audit package readiness.
5) What supply chain step most commonly delays regulatory-ready product release?
CMC documentation updates tied to DMF/ASMF references and change-control implementation at the formulation site often drive the longest timelines.
References
- FDA. “ANDA Regulations: Drug Master Files.” US Food and Drug Administration.
- European Medicines Agency. “Procedural advice on submitting variations.” EMA.
- USP. “USP-NF Monographs for Donepezil Hydrochloride and Memantine Hydrochloride.” United States Pharmacopeia.
